TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07310446: Collection of Samples From the United States Population for Optimization and Evaluation of Colorectal Cancer (CRC) Plasma Circulating Free-DNA (cfDNA) Marker Panel Performance

Sponsor: Universal Diagnostics · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 6500 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT07310446 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07310446 Rescue Dossier →